Business Editors/Health/Medical Writers
MIAMI–(BUSINESS WIRE)–Dec. 8, 2003
IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced that its wholly owned subsidiary, IVAX Pharmaceuticals, Inc. is distributing amoxicillin with clavulanate potassium, supplied and licensed by GlaxoSmithKline (LSE and NYSE:GSK). Amoxicillin with clavulnate potassium is an oral antibacterial combination used for the treatment of respiratory, urinary and skin infections; and is the generic equivalent of Augmentin(R), which is marketed by GlaxoSmithKline. U.S. sales for amoxicillin with clavulanate potassium were $1.4 billion for the twelve months ending September 30, 2003.

Related Results

Amoxil approved for twice-daily pediatric use

Drug events regularly populate EDs

Teva Pharmaceutical Industries

Production breakthrough in pharmaceutical intermediate of D-(-)-p-hydroxy phe…

Some Facelift Patients Infected With MRSA 'Superbug'

IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally.
Copies of this and other news releases may be obtained free of charge from IVAX’ website at http://www.ivax.com.
COPYRIGHT 2003 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

source